Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01555710




Registration number
NCT01555710
Ethics application status
Date submitted
12/03/2012
Date registered
15/03/2012
Date last updated
21/05/2013

Titles & IDs
Public title
Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)
Scientific title
A Multi-center, Open-Label, Adaptive, Randomized Study of Palifosfamide-tris, a Novel DNA Crosslinker, in Combination With Carboplatin and Etoposide (PaCE) Chemotherapy Versus Carboplatin and Etoposide (CE) Alone in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer. The MATISSE Study
Secondary ID [1] 0 0
IPM3002
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Extensive-Stage Small Cell Lung Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Carboplatin
Treatment: Drugs - Palifosfamide-tris
Treatment: Drugs - Etoposide
Treatment: Drugs - Carboplatin

Experimental: Palifosfamide-tris plus Carboplatin and Etoposide - Drug: palifosfamide-tris in combination with carboplatin and etoposide palifosfamide-tris: 130 mg/m2/day 3 days every 21 days for a max of 6 cycles. carboplatin: AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a max of 6 cycles.

Active comparator: Carboplatin plus Etoposide - Drug: carboplatin in combination with etoposide carboplatin: AUC 5mg/mL/min 1 day every 21 days for a maximum of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.


Treatment: Drugs: Carboplatin
AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles.

Treatment: Drugs: Palifosfamide-tris
130 mg/m2/day 3 days every 21 days for a max of 6 cycles.

Treatment: Drugs: Etoposide
100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.

Treatment: Drugs: Carboplatin
AUC 5 mg/mL/min 1 day every 21 days for a max of 6 cycles.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
Assessed every 12 weeks for survival until 1 year following completion of enrollment
Secondary outcome [1] 0 0
Progression Free Survival (PFS)
Timepoint [1] 0 0
Assessed every 6 weeks for 22 weeks, then every 12 weeks until progressive disease, initiation of alternate anticancer therapy, or 1 year following the last patient enrolled (whichever is soonest)
Secondary outcome [2] 0 0
Quality of Life (QOL) as assessed by EQ-5D-3L and QLQ-LC13
Timepoint [2] 0 0
Assessed every 3 weeks for 22 weeks, then every 12 weeks until 1 year following the last patient enrolled
Secondary outcome [3] 0 0
Objective Response Rate (ORR)
Timepoint [3] 0 0
Assessed every 6 weeks for 22 weeks, then every 12 weeks until a partial or complete response is confirmed
Secondary outcome [4] 0 0
Response Duration
Timepoint [4] 0 0
Time from the date of first objective response (partial or complete response), with subsequent confirmation, until the date of disease progression or the occurrence of death
Secondary outcome [5] 0 0
Safety parameters (number of adverse events as well as number of findings from physical examinations, ECGs, vital signs, and clinical laboratory results)using NCI CTCAE v. 4.03
Timepoint [5] 0 0
22 weeks

Eligibility
Key inclusion criteria
* Documented extensive-stage small cell lung cancer.
* Patient has received no prior chemotherapy, adjuvant therapy, or radiotherapy for lung cancer.
* ECOG Performance Status of 0, 1 or 2.
* Adequate bone marrow and organ function based on the results of protocol- specified laboratory tests.
* Male and female patients must agree to use a highly reliable method of birth control during study participation.
* Able to provide informed consent
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Previously untreated (non-irradiated), symptomatic brain metastases.
* Known allergy to any of the study drugs or their excipients.
* Any unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a patient and/or their compliance with the protocol, based on screening tests, physical examination and medical history (as specifically defined in the clinical protocol).
* Any malignancy other than small cell lung cancer within the last 5 years prior to randomization, with the exception of cervical carcinoma in situ, nonmelanoma skin cancer, or superficial bladder tumors (Ta, Tis, or T1) that have been successfully and curatively treated with no evidence of recurrent or residual disease. (Exception: Subjects with a history of malignancy other than small cell lung cancer may be enrolled after consultation with the medical monitor provided the patient's prognosis is best defined by the extensive-stage small cell lung cancer).
* Currently pregnant or nursing.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
UNKNOWN
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/05/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/06/2015
Actual
Sample size
Target
548
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Southern Medical Day Oncology Care Centre - Wollongong
Recruitment postcode(s) [1] 0 0
2500 - Wollongong
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Delaware
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Maryland
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Minnesota
Country [14] 0 0
United States of America
State/province [14] 0 0
New Jersey
Country [15] 0 0
United States of America
State/province [15] 0 0
New Mexico
Country [16] 0 0
United States of America
State/province [16] 0 0
New York
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Pennsylvania
Country [19] 0 0
United States of America
State/province [19] 0 0
South Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
Vermont
Country [22] 0 0
United States of America
State/province [22] 0 0
Virginia
Country [23] 0 0
United States of America
State/province [23] 0 0
Washington
Country [24] 0 0
United States of America
State/province [24] 0 0
Wisconsin
Country [25] 0 0
Canada
State/province [25] 0 0
Manitoba
Country [26] 0 0
Canada
State/province [26] 0 0
Ontario
Country [27] 0 0
Canada
State/province [27] 0 0
Quebec
Country [28] 0 0
France
State/province [28] 0 0
Basse-normandie
Country [29] 0 0
France
State/province [29] 0 0
Bretagne
Country [30] 0 0
France
State/province [30] 0 0
Centre
Country [31] 0 0
France
State/province [31] 0 0
Limousin, Lorraine
Country [32] 0 0
France
State/province [32] 0 0
Pays de La Loire
Country [33] 0 0
France
State/province [33] 0 0
Provence Alpes Cote D'azur
Country [34] 0 0
France
State/province [34] 0 0
Rhone-alpes
Country [35] 0 0
France
State/province [35] 0 0
Strasbourg
Country [36] 0 0
Hungary
State/province [36] 0 0
Hajdu-bihar
Country [37] 0 0
Hungary
State/province [37] 0 0
Heves
Country [38] 0 0
Israel
State/province [38] 0 0
Haifa
Country [39] 0 0
Israel
State/province [39] 0 0
Jerusalem
Country [40] 0 0
Israel
State/province [40] 0 0
Kfar Saba
Country [41] 0 0
Israel
State/province [41] 0 0
Nahariya
Country [42] 0 0
Israel
State/province [42] 0 0
Petah Tiqwa
Country [43] 0 0
Italy
State/province [43] 0 0
Genova
Country [44] 0 0
Italy
State/province [44] 0 0
Milano
Country [45] 0 0
Italy
State/province [45] 0 0
Trento
Country [46] 0 0
Poland
State/province [46] 0 0
Mazowieckie
Country [47] 0 0
Poland
State/province [47] 0 0
Pomorskie
Country [48] 0 0
Poland
State/province [48] 0 0
Zachodniopomorskie
Country [49] 0 0
Russian Federation
State/province [49] 0 0
Bashkortostan
Country [50] 0 0
Russian Federation
State/province [50] 0 0
Moscow
Country [51] 0 0
Russian Federation
State/province [51] 0 0
Primorskiy
Country [52] 0 0
Russian Federation
State/province [52] 0 0
Tatarstan
Country [53] 0 0
Russian Federation
State/province [53] 0 0
Chelaybinsk
Country [54] 0 0
Russian Federation
State/province [54] 0 0
Ivanovo
Country [55] 0 0
Russian Federation
State/province [55] 0 0
Nizhny Novgorod
Country [56] 0 0
Russian Federation
State/province [56] 0 0
Saint Petersburg
Country [57] 0 0
Russian Federation
State/province [57] 0 0
Saint-Petersburg
Country [58] 0 0
Russian Federation
State/province [58] 0 0
Yaroslavl
Country [59] 0 0
Taiwan
State/province [59] 0 0
Taichung
Country [60] 0 0
United Kingdom
State/province [60] 0 0
England

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Alaunos Therapeutics
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT01555710